Skip to Content

Lutathera Approval Status

  • FDA approved: No
  • Brand name: Lutathera
  • Company: Advanced Accelerator Applications S.A.
  • Treatment for: Neuroendocrine Carcinoma

Lutathera (177Lu-DOTATATE) is a Lu-177-labeled somatostatin analogue peptide in development for the treatment of gastroenteropancreatic neuroendocrine tumors.

Development Status and FDA Approval Process for Lutathera

DateArticle
Jun 27, 2016Advanced Accelerator Applications Announces FDA Priority Review for Lutathera

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide